1. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such as corneal opacities and scars, dystrophies, epithelial scarring, infections, blood clots, etc. 
2. Best corrected visual acuity (BCVA) at baseline <20/200. 
3. Has a condition or history that, in the opinion of the investigator, may interfere significantly with the subject's participation in the study. 
4. A woman who is pregnant, nursing an infant, or planning a pregnancy. 
5. Has a known adverse reaction and/or sensitivity to the study drug or its components. 
6. Routine use (more than twice a week) of a chlorinated swimming pool. 
7. Unwilling or unable to cease using the following medications during the study period: Topical ocular cyclosporine (e.g. Restasis®), anti-histamines, antipsychotics, or eye gels. 
8. Currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.       
    

NCT02656394_exc_T12
Condition
corneal opacities
NCT02656394_exc_T13
Condition
corneal scars
NCT02656394_exc_T14
Condition
dystrophies
NCT02656394_exc_T15
Condition
epithelial scarring
NCT02656394_exc_T16
Condition
infections
NCT02656394_exc_T17
Condition
blood clots
NCT02656394_exc_T18
Condition
eye conditions
NCT02656394_exc_T19
Qualifier
will interfere with study assessments
NCT02656394_exc_T20
Scope
corneal opacities and scars, dystrophies, epithelial scarring, infections, blood clots
NCT02656394_exc_T21
Measurement
Best corrected visual acuity (BCVA)
NCT02656394_exc_T22
Value
<20/200
NCT02656394_exc_T23
Temporal
at baseline
NCT02656394_exc_T24
Reference_point
baseline
NCT02656394_exc_T25
Person
woman
NCT02656394_exc_T26
Condition
pregnant
NCT02656394_exc_T30
Condition
nursing
NCT02656394_exc_T32
Condition
pregnancy
NCT02656394_exc_T33
Condition
adverse reaction to the study drug or its components
NCT02656394_exc_T34
Condition
sensitivity to the study drug or its components
NCT02656394_exc_T35
Multiplier
more than twice a week
NCT02656394_exc_T36
Multiplier
Routine use
NCT02656394_exc_T37
Observation
chlorinated swimming pool
NCT02656394_exc_T41
Drug
Topical ocular cyclosporine
NCT02656394_exc_T42
Drug
Restasis®
NCT02656394_exc_T43
Drug
anti-histamines
NCT02656394_exc_T44
Drug
antipsychotics
NCT02656394_exc_T45
Drug
eye gels
NCT02656394_exc_T46
Temporal
during the study period
NCT02656394_exc_T47
Reference_point
study period
NCT02656394_exc_T48
Scope
Topical ocular cyclosporine (e.g. Restasis®), anti-histamines, antipsychotics, or eye gels
NCT02656394_exc_T49
Drug
investigational drug
NCT02656394_exc_T51
Device
investigational device
NCT02656394_exc_T53
Drug
investigational drug
NCT02656394_exc_T55
Temporal
within 30 days prior to Visit 1
NCT02656394_exc_T56
Reference_point
Visit 1
NCT02656394_exc_T57
Device
investigational device
NCT02656394_exc_T58
Scope
investigational drug or device study or have used an investigational drug or device